Compare Goodyear Tire & Rubber Co (GT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Vertex Pharmaceuticals Incorporated — how do they compare? Goodyear Tire & Rubber Co trades at $6.1 (market cap $1.74B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 76.3× Goodyear Tire & Rubber Co's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| GT | VRTX | |
|---|---|---|
Market Cap | $1.74B | $132.79B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $529.65 |
52-Week Low | $5.58 | $376.62 |
Enterprise Value | $9.09B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) is trading at $6.44, down 4.73% today, reflecting ongoing pressure from declining tire volumes and a challenging cost environment. The stock exhibits a bearish technical trend with oversold RSI levels, while fundamentals show a net loss of $1.72 billion in 2025 despite positive cash flow. Recent Q2 2026 results missed earnings expectations but beat revenue estimates, highlighting mixed operational performance amid market headwinds.
The outlook remains cautious with persistent profitability challenges and high debt levels offsetting low valuation multiples. Investment opportunity hinges on volume recovery and cost management improvements, but risks include sustained margin pressure and competitive threats. Analyst sentiment is mixed with a slight hold bias, underscoring the need for operational turnaround to drive shareholder value.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
